Form 8-K - Current report:
SEC Accession No. 0001558370-21-015503
Filing Date
2021-11-10
Accepted
2021-11-10 16:19:21
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K olma-20211110x8k.htm   iXBRL 8-K 38511
2 EX-99.1 olma-20211110xex99d1.htm EX-99.1 125052
3 GRAPHIC olma-20211110xex99d1002.jpg GRAPHIC 21738
  Complete submission text file 0001558370-21-015503.txt   329163

Data Files

Seq Description Document Type Size
4 EX-101.SCH olma-20211110.xsd EX-101.SCH 3024
5 EX-101.LAB olma-20211110_lab.xml EX-101.LAB 16737
6 EX-101.PRE olma-20211110_pre.xml EX-101.PRE 10605
7 EXTRACTED XBRL INSTANCE DOCUMENT olma-20211110x8k_htm.xml XML 5106
Mailing Address 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107
Business Address 512 2ND STREET, 4TH FLOOR SAN FRANCISCO CA 94107 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39712 | Film No.: 211396934
SIC: 2834 Pharmaceutical Preparations